omega therapeutics™ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. the company’s platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. we are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines
Company profile
Ticker
OMGA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Omega Therapeutics Security Corporation ...
OMGA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
16 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
28 Mar 24
8-K
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop a Novel Therapeutic for Obesity Management
5 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
11 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
9 Nov 23
8-K
Other Events
26 Sep 23
8-K
Entry into a Material Definitive Agreement
22 Sep 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 82.11 mm | 82.11 mm | 82.11 mm | 82.11 mm | 82.11 mm | 82.11 mm |
Cash burn (monthly) | 7.92 mm | (no burn) | 7.63 mm | 9.21 mm | 7.68 mm | 8.22 mm |
Cash used (since last report) | 54.23 mm | n/a | 52.25 mm | 63.04 mm | 52.56 mm | 56.27 mm |
Cash remaining | 27.88 mm | n/a | 29.86 mm | 19.07 mm | 29.55 mm | 25.84 mm |
Runway (months of cash) | 3.5 | n/a | 3.9 | 2.1 | 3.8 | 3.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 60 |
Opened positions | 17 |
Closed positions | 12 |
Increased positions | 16 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 271.83 bn |
Total shares | 75.98 mm |
Total puts | 24.40 k |
Total calls | 37.00 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Flagship Pioneering | 29.23 mm | $163.66 bn |
Flagship Ventures Fund V | 22.24 mm | $128.55 mm |
FMR | 5.43 mm | $30.43 bn |
Harbourvest Partners | 3.51 mm | $19.67 bn |
HarbourVest Partners | 2.65 mm | $29.99 mm |
Artal | 2.53 mm | $14.19 mm |
State Of Wisconsin Investment Board | 1.86 mm | $10.41 bn |
BLK Blackrock | 1.61 mm | $9.01 bn |
Vanguard | 1.48 mm | $8.31 bn |
CHI Advisors | 1.06 mm | $5.91 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 24 | Ling Zeng | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 125,000 | 448.75 k | 125,000 |
7 Feb 24 | Joshua Reed | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 110,000 | 394.90 k | 110,000 |
7 Feb 24 | Schade Christian S | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 512,848 | 1.84 mm | 512,848 |
7 Feb 24 | Yan Moore | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 110,000 | 394.90 k | 110,000 |
7 Feb 24 | Thomas McCauley | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 75,000 | 269.25 k | 75,000 |
7 Feb 24 | Thomas McCauley | Stock Option Common Stock | Grant | Acquire A | No | No | 3.59 | 125,000 | 448.75 k | 125,000 |
News
Omega Therapeutics Presents New Preclinical Data Supporting The Potential Of Precision Epigenomic Control At AACR 2024
9 Apr 24
Piper Sandler Reiterates Overweight on Omega Therapeutics, Lowers Price Target to $9
3 Apr 24
Omega Therapeutics Q4 2023 GAAP EPS $(0.37) Beats $(0.47) Estimate
28 Mar 24
How Is The Market Feeling About Omega Therapeutics?
26 Jan 24
Press releases
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
9 Apr 24
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
8 Apr 24
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
28 Mar 24
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
19 Mar 24
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
6 Mar 24